SCHEMBL296509

SCHEMBL296509

CNCc1ccc(C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
KDM4E B2RXH2 2/20 0.56
CYP3A4 P08684 1/20 0.56
LOXL2 Q9Y4K0 1/20 0.56
CHRM2 P08172 1/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NCF1 P14598 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
GAA P10253 1/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
CASP1 P29466 1/20 0.48
BLM P54132 1/20 0.48
PLEC Q15149 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25007868 0.93 MAPT (0.50) MAPTKDM4ECYP3A4LOXL2CHRM2
SCHEMBL22882372 0.93 CHRM2 (0.57) MAPTKDM4ECYP3A4LOXL2CHRM2
SCHEMBL2504209 0.88 KDM4E (0.68) MAPTKDM4ECYP3A4LOXL2NCF1
SCHEMBL26761783 0.87 MAPK14 (0.51) MAPTKDM4ECYP3A4LOXL2CHRM2
SCHEMBL28649867 0.87 LOXL2 (0.61) MAPTKDM4ECYP3A4LOXL2CHRM2
Hydrochloric Acid SCHEMBL30925271 0.85 KDM4E (0.74) MAPTKDM4ECYP3A4LOXL2NCF1
SCHEMBL26019455 0.83 CES2 (0.61) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL842161 0.80 CHRM2 (0.67) MAPTKDM4ECYP3A4CHRM2MEN1
SCHEMBL13184538 0.80 KDM4E (0.59) MAPTKDM4ECYP3A4LOXL2MEN1
SCHEMBL16255071 0.79 CHRM2 (0.48) MAPTKDM4ECHRM2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119371674-A Preparation method of donor-acceptor type metal organic framework photocatalyst and application of photocatalytic amine oxide/thioether 长沙理工大学 2025-01-28 CN claimed
CN-117886718-B Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound 内蒙古工业大学 2024-05-24 CN claimed
CN-117886718-A Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound 内蒙古工业大学 2024-04-16 CN claimed
CN-117383994-A Preparation method of asymmetric urea compound and asymmetric urea compound 内蒙古工业大学 2024-01-12 CN claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
CN-101410366-A Substituted bicyclic ring derivatives and uses thereof ASAHI KASEI PHARMA CORP (JP) 2009-04-15 CN claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-21 US claimed
WO-2008100618-A2 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
JP-6025023-A None JP disclosed
CN-119371674-A Preparation method of donor-acceptor type metal organic framework photocatalyst and application of photocatalytic amine oxide/thioether 长沙理工大学 2025-01-28 CN disclosed
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO disclosed
EP-4393937-A1 STEROID COMPOUND AND CONJUGATE THEREOF Duality Biologics (Suzhou) Co., Ltd. (CN) 2024-07-03 EP disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
EP-0186817-B1 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1989-08-02 EP disclosed
EP-0274259-A2 New renin-inhibitory oligopeptides, their preparaton and their use Sankyo Company Limited (JP) 1988-07-13 EP disclosed
EP-0186817-A1 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-07-09 EP disclosed
US-3985729-A ANTIINFLAMMATORY AGENTS; CYCLIZATION OF 3-BENZYLAMINO-ALKYL-INDAN-1-OLS SANDOZ, INC. (US) 1976-10-12 US disclosed
US-3976634-A ANTIINFLAMMATORY SANDOZ, INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 MAPT 1/4885KDM4E 4298/4885CYP3A4 4693/4885
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R MAPT 4848/4885KDM4E 2981/4885CYP3A4 1212/4885
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ MAPT 1156/4885KDM4E 3317/4885CYP3A4 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.